Streetwise Live! Presents Algernon Pharmaceuticals on 02/10/2022. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Co. Meets Goals in COVID Drug Trial

Share on Stocktwits


The Quick Take

  • Todos Medical reports that the Phase 2 study of its COVID-19 antiviral 3CL protease inhibitor Tollovir closed early after analysis of positive interim data.
  • The drug met its primary endpoint of reducing time to clinical improvement of hospitalized (severe and critical) COVID-19 patients.
  • In the trial, the average reduction of time to clinical improvement was 2.7 days in the Tollovir group versus the placebo group, the company said.
  • There were 0% COVID-related deaths in the Tollovir group versus 22% in the placebo group.
  • Shaare Zedek Medical Center in Jerusalem now permits the use of Tollovir in hospitalized COVID-19 patients on a compassionate use basis.
  • Todos Medical is preparing a Phase 2/3 trial to support Emergency Use Authorizations of the drug.

Todos Medical (TOMDF:OTCQB) announced positive interim data for its antiviral 3CL protease inhibitor Tollovir in its Phase 2 clinical trial for the treatment of critically hospitalized COVID-19 patients.

The "future appears very bright for TOMDF investors."
—Vision and Value, Sector Expert




The drug met the study's primary goal of reducing time to clinical improvement and also met several other key goals, including reducing the overall number of COVID-19 deaths, Todos Medical and joint venture partner NLC Pharma Ltd. said.

Because of the positive data, Todos Medical has formally closed the Phase 2 trial. Tollovir will now also be permitted on a compassionate use basis at Shaare Zedek Medical Center in Jerusalem.

“The recent emergence of the Omicron variant has been pushing healthcare systems to the brink of collapse,” said Dr. Dorit Arad, founder and chief technology officer of NLC Pharma. “Tollovir could be an incredibly powerful tool to reduce death and stabilize patients faster, thereby reducing their recovery time from this debilitating disease. Tollovir will help flatten the curve by freeing up hospital capacity to see more patients and perform other more routine non-COVID related hospital treatments.”

Todos Medical President and Chief Executive Officer Gerald E. Commissiong said the companies were in the process of fine tuning clinical study protocols for additional studies needed for emergency use.

“We have already begun preparing manufacturing for commercial quantities of Tollovir so that we will be able to deliver shipments in jurisdictions where we expect to be granted accelerated Emergency Use Authorization (EUA),” Commissiong said. "Our goal is to immediately target EUA in jurisdictions that will require limited additional clinical data.”

Tollovir is also being developed for the treatment of pediatric COVID-19 hospitalizations, moderate to severe adult outpatient COVID-19, moderate to severe pediatric outpatient COVID-19, adult Long COVID, and pediatric Long COVID, Commissiong said.

According to one sector expert, the "future appears very bright for TOMDF investors." Click here for additional insight from Vision and Value. 



1) Steve Sobek compiled this article for Streetwise Reports LLC. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Todos Medical. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. 
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe